Validus Announces Superior Proposal for Combination with Transatlantic Holdings
- Transatlantic Stockholders to Receive Total Consideration of
$55.95 per Share, Consisting of 1.5564 Validus Voting Common Shares and Special Pre-Closing Dividend of$8.00 Per Share in Cash - Proposal Offers 27.1% Premium to
June 10, 2011 Transatlantic Stock Price and 12.1% Premium to Transatlantic Acquisition byAllied World - Transaction Structured to be Tax-Free
- Transaction Would Create Current and Long-Term Value for Transatlantic Stockholders and Global Reinsurance Leader
In addition to the meaningful premium and cash consideration, the proposed transaction with Validus is structured to be tax-free to Transatlantic stockholders with respect to the Validus voting common shares they receive in the merger (unlike the fully-taxable proposed acquisition of Transatlantic by
“Our proposal represents a compelling strategic combination that will generate superior value for both Validus and Transatlantic shareholders. We will create a broadly diversified global reinsurance leader,” stated
Validus is fully committed to completing a transaction with Transatlantic and believes its proposal clearly constitutes a “Superior Proposal” under the terms of Transatlantic’s merger agreement with
Conference Call
Validus will hold a conference call for investors, analysts, and other interested parties on
Presented below is the full text of the letter sent to the Board of Directors of Transatlantic:
July 12, 2011 |
Board of Directors of Transatlantic Holdings, Inc. |
c/o Richard S. Press, Chairman |
c/o Robert F. Orlich, President and Chief Executive Officer |
80 Pine Street New York, New York 10005 |
Re:Superior Proposal by
Dear Sirs:
On behalf of Validus, I am pleased to submit this proposal to combine the businesses of Validus and Transatlantic through a merger in which Validus would acquire all of the outstanding stock of Transatlantic. Pursuant to our proposal, Transatlantic stockholders would receive 1.5564 Validus voting common shares in the merger and
Based on our closing stock price on
Our Board of Directors and senior management have great respect for Transatlantic and its business. As you know from our previous outreaches to you and past discussions, including our recent conversation on
We believe that our proposal clearly constitutes a “Superior Proposal” under the terms of the proposed
1. |
Superior Value. Our proposal of 1.5564 Validus voting common shares in the merger and $8.00 in cash pursuant to a pre-closing dividend for each share of Transatlantic common stock, which represents total consideration of $55.95 per share of Transatlantic common stock based on the Validus closing price on July 12, 2011, delivers a significantly higher value to Transatlantic stockholders than does the proposed acquisition of Transatlantic by Allied World. As noted above, as of such date, our proposal represents a 27.1% premium to Transatlantic’s closing price on June 10, 2011, the last trading day prior to the announcement of the proposed acquisition of Transatlantic by Allied World, and a 12.1% premium over the value of stock consideration to be paid to Transatlantic stockholders in the proposed acquisition of Transatlantic by Allied World based on the closing prices of Allied World and Transatlantic shares on July 12, 2011. Our proposal also delivers greater certainty of value because it includes a meaningful pre-closing cash dividend payable to Transatlantic stockholders in contrast to the all-stock Allied World offer. |
|
2. |
Tax-Free Treatment. In addition to the meaningful premium and cash consideration, the proposed transaction with Validus is structured to be tax-free to Transatlantic stockholders with respect to the Validus voting common shares they receive in the merger (unlike the fully-taxable proposed acquisition of Transatlantic by Allied World). |
|
3. |
Relative Ownership. Upon consummation of the proposed transaction, Transatlantic stockholders would own approximately 48% of Validus’ outstanding common shares on a fully-diluted basis.1 |
|
4. |
Superior Currency. Validus’ voting common shares have superior performance and liquidity characteristics compared to Allied World’s stock: |
Validus |
Allied World |
|||||||
Total Shareholder Return Since Validus IPO(a) |
+55% |
+24% |
||||||
Market Cap as of 6/10/11 | $3.0 billion | $2.2 billion | ||||||
Average Daily Trading Volume (3 month)(b) | $27.6 million | $14.6 million | ||||||
Average Daily Trading Volume (6 month)(c) | $22.4 million | $13.4 million | ||||||
Price / As-Reported Diluted Book (Unaffected)(d) |
0.97x |
0.78x | ||||||
Price / As-Reported Diluted Book (Current)(d) | 0.98x | 0.76x | ||||||
Dividend Yield as of 6/10/11 (Unaffected) |
3.3%(e) |
2.6%(f) |
||||||
(a) Including dividends. Based on the closing prices on June 10, 2011 and July 24, 2007. Source: SNL. | ||||||||
(b) Three months prior to June 12, 2011, date of announcement of proposed Allied World acquisition of Transatlantic. Source: Bloomberg. | ||||||||
(c) Six months prior to June 12, 2011, date of announcement of proposed Allied World acquisition of Transatlantic. Source: Bloomberg. | ||||||||
(d) Based on March 31, 2011 GAAP diluted book value per share. Unaffected price / as-reported diluted book value measured prior to June 12, 2011 announcement of proposed Allied World acquisition of Transatlantic. Current is as of closing prices of Validus and Allied World stock on July 12, 2011. | ||||||||
(e) Based on $0.25 per share quarterly dividend, as announced May 5, 2011. | ||||||||
(f) Based on $0.375 per share quarterly dividend, as disclosed in Allied World Form 8-K dated June 15, 2011. | ||||||||
Moreover, Validus has maintained a premium valuation on a diluted book value per share multiple basis relative to its peers over the past two years, including
5. Robust Long-Term Prospects. We believe that a combined Validus and Transatlantic would be a superior company to
- Strategic Fit:
- The combination of Validus’ strong positions in
Bermuda andLondon and Transatlantic’s operations inthe United States , continentalEurope andAsia would produce a rare example of a complementary business fit with minimal overlap. - This combination will produce a well-diversified company that will be a global leader in reinsurance.
- This combination will solidify Validus’ leadership in property catastrophe, with pro forma managed catastrophe premiums of over
$1 billion ,2 while remaining within Validus’ historical risk appetite. Validus has significant experience assimilating catastrophe portfolios, most recently its acquisition ofIPC Holdings, Ltd. in 2009. - Finally, we believe that there is a natural division of expertise among our key executives in line with our complementary businesses.
- The combination of Validus’ strong positions in
- Size and Market Position: This combination would create a geographically diversified company with a top six reinsurance industry position on a pro forma basis,3 and makes the combined company meaningfully larger than many of the companies considered to be in our mutual peer group. Our merged companies would have gross premiums written over the last twelve months of approximately
$6.1 billion as ofMarch 31, 2011 .- As the level of capital required to support risk will continue to rise globally, we believe that size will become an even more important competitive advantage in the reinsurance market. The recent renewals at
June 1 andJuly 1, 2011 reinforced this belief as Validus was able to significantly outperform market rate levels – which we believe was a result of our size, superior analytics and our ability to structure private transactions at better than market terms, while not increasing our overall risk levels.
- As the level of capital required to support risk will continue to rise globally, we believe that size will become an even more important competitive advantage in the reinsurance market. The recent renewals at
- Significant Structural Flexibility: Given jurisdiction, size and market position benefits, a combined Validus and Transatlantic would have significant structural flexibility, including its ability to optimally deploy capital globally in different jurisdictions, e.g., through targeted growth initiatives and/or capital management.
- Global, Committed Leader in Reinsurance: Validus has a superior business plan for the combined company that will drive earnings by capturing the best priced segments of the reinsurance market. A combined Validus / Transatlantic would derive a majority of its premiums from short-tail lines and 17% of premiums written from property catastrophe (compared to 10% for
Allied World / Transatlantic).4 Validus believes this business mix allows for optimal cycle management as the attractive pricing in short tail reinsurance will allow the combined company to better position itself for the eventual upturn in long tail lines. Validus also intends to fortify Transatlantic’s reserve position through a planned$500 million pre-tax reserve strengthening.
We have reviewed the
Additionally, we expect that the proposed transaction with Validus would be subject to customary closing conditions, including the receipt of domestic and foreign antitrust and insurance regulatory approvals and consents in
Validus expects that the pre-closing special dividend would be financed entirely by new indebtedness incurred by Transatlantic. As such, Validus has received a highly confident letter from
Validus has completed two large acquisitions since 2007, and has a proven track record of assimilating and enhancing the performance of businesses that it acquires to create additional value for shareholders. As such, we are confident that we will be able to successfully integrate Transatlantic’s and Validus’ businesses in a manner that will quickly maximize the benefits of the transaction for our respective shareholders.
Given the importance of our proposal to our respective shareholders, we feel it appropriate to make this letter public. We believe that our proposal presents a compelling opportunity for both our companies and our respective shareholders, and look forward to the Transatlantic Board of Directors’ response by
We understand that, after the Transatlantic Board of Directors has made this determination and provided the appropriate notice to
We understand that the terms of Transatlantic’s merger agreement with
We have already reviewed Transatlantic’s publicly available information and would welcome the opportunity to review the due diligence information that Transatlantic previously provided to
Our Board of Directors has unanimously approved the submission of this proposal. Of course, any definitive transaction between Validus and Transatlantic would be subject to the final approval of our Board of Directors, and the issuance of Validus voting common shares contemplated by our proposal will require the approval of our shareholders. We do not anticipate any difficulty in obtaining the required approvals and are prepared to move forward promptly at an appropriate time to seek these approvals.
This letter does not create or constitute any legally binding obligation by Validus regarding the proposed transaction, and, other than any confidentiality agreement to be entered into with Transatlantic, there will be no legally binding agreement between us regarding the proposed transaction unless and until a definitive merger agreement is executed by Transatlantic and Validus.
We believe that time is of the essence, and we, our financial advisors,
Sincerely,
/s/
Enclosure
About
Cautionary Note Regarding Forward-Looking Statements
This press release may include forward-looking statements, both with respect to Validus and its industry, that reflect Validus’ current views with respect to future events and financial performance. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “anticipate,” “will,” “may,” “would” and similar statements of a future or forward-looking nature are often used to identify forward-looking statements. All forward-looking statements address matters that involve risks and uncertainties, many of which are beyond Validus’ control. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements. Validus believes that these factors include, but are not limited to, the following: 1) uncertainty as to whether Validus will be able to enter into or consummate the proposed transaction on the terms set forth in Validus’ proposal; 2) uncertainty as to the actual premium that will be realized by Transatlantic stockholders in connection with the proposed transaction; 3) failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the transaction or integrating the businesses of Validus and Transatlantic; 4) uncertainty as to the long-term value of Validus voting common shares; 5) unpredictability and severity of catastrophic events; 6) rating agency actions; 7) adequacy of Validus’ or Transatlantic’s risk management and loss limitation methods; 8) cyclicality of demand and pricing in the insurance and reinsurance markets; 9) Validus’ ability to implement its business strategy during “soft” as well as “hard” markets; 10) adequacy of Validus’ or Transatlantic’s loss reserves; 11) continued availability of capital and financing; 12) retention of key personnel; 13) competition in the insurance and reinsurance markets; 14) potential loss of business from one or more major reinsurance or insurance brokers; 15) the credit risk Validus assumes through its dealings with its reinsurance and insurance brokers; 16) Validus’ or Transatlantic’s ability to implement, successfully and on a timely basis, complex infrastructure, distribution capabilities, systems, procedures and internal controls, and to develop accurate actuarial data to support the business and regulatory and reporting requirements; 17) general economic and market conditions (including inflation, volatility in the credit and capital markets, interest rates and foreign currency exchange rates); 18) the integration of businesses Validus may acquire or new business ventures Validus may start; 19) the legal, regulatory and tax regimes under which Validus operates; 20) the effect on Validus’ or Transatlantic’s investment portfolios of changing financial market conditions, including inflation, interest rates, liquidity and other factors; 21) acts of terrorism or outbreak of war or hostilities; and 22) availability of reinsurance and retrocessional coverage, as well as management’s response to any of the aforementioned factors.
The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the Risk Factors included in Validus’ and Transatlantic’s most recent reports on Form 10-K and Form 10-Q and other documents of Validus and Transatlantic on file with the
Third Party-Sourced Information:
Certain information included in this presentation has been sourced from third parties. Validus does not make any representations regarding the accuracy, completeness or timeliness of such third party information. Permission to quote third party sources has neither been sought nor obtained.
Additional Information about the Proposed Transaction and Where to Find It:
This press release relates to a proposed business combination transaction between Validus and Transatlantic which may become the subject of a registration statement and relevant solicitation materials filed by Validus with the
Participants in the Solicitation:
Validus and certain of its directors and officers may be deemed to be participants in any solicitation of shareholders in connection with the proposed transaction. Information about Validus’ directors and officers is available in Validus’ proxy statement, dated
_____________________________ | ||
(1) |
Fully diluted shares calculated using treasury stock method. |
|
(2) |
Based on property catastrophe gross premiums written for Validus and net premiums written for Transatlantic in 2010. Pro forma for Validus ($572 million), Transatlantic ($431 million) and AlphaCat Re 2011 ($43 million). |
|
(3) |
Ranked by 2009 net premiums written and excluding the Lloyd’s market per Standard & Poor’s Global Reinsurance Highlights 2010. |
|
(4) |
Based on gross premiums written for Validus and net premiums written for Transatlantic in 2010. |
Investors:
President and Chief Financial Officer
or
or
Media:
Sard Verbinnen & Co
Source:
Group Practice Leaders Accelerate Growth with Marketing Expertise From 1-800-DENTIST®
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News